{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:00:57Z","timestamp":1788354057003,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cbpa.2026.102655","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:34:48Z","timestamp":1772102088000},"page":"102655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeted protein degradation as a novel therapeutic strategy against infectious diseases"],"prefix":"10.1016","volume":"91","author":[{"given":"Lyn-Mari\u00e9","family":"Birkholtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiaan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyrick","family":"Welcome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9898-8226","authenticated-orcid":false,"given":"Erick","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2026.102655_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2026.102655_bib2","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2214-109X(23)00539-9","article-title":"The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis","volume":"12","author":"Sartorius","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.cbpa.2026.102655_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Martin-Acosta","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cells12141846","article-title":"Targeted protein degradation: principles and applications of the proteasome","volume":"12","author":"Kim","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cbpa.2026.102655_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cbpa.2026.102655_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.cbpa.2026.102655_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs - a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102655_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102655_sref11","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.cbpa.2026.102655_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cbpa.2026.102655_sref13","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs mediate targeted protein degradation in bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2026.102655_sref14","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.cell.2023.04.009","article-title":"Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival","volume":"186","author":"Hoi","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2026.102655_bib15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41467-024-46218-7","article-title":"Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria","volume":"15","author":"Junk","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102655_bib16","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fmolb.2021.669762","article-title":"Applications of bacterial degrons and degraders \u2014 toward targeted protein degradation in bacteria","volume":"8","author":"Izert","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.cbpa.2026.102655_sref17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsbiomedchemau.2c00063","article-title":"Targeted protein degradation for infectious diseases: from basic biology to drug discovery","volume":"3","author":"Espinoza-Chavez","year":"2023","journal-title":"ACS Bio & Med Chem Au"},{"key":"10.1016\/j.cbpa.2026.102655_bib18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1042\/BCJ20230191","article-title":"Targeting bacterial degradation machinery as an antibacterial strategy","volume":"480","author":"Petkov","year":"2023","journal-title":"Biochem J"},{"key":"10.1016\/j.cbpa.2026.102655_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/17460441.2023.2178413","article-title":"PROTAC antibiotics: the time is now","volume":"18","author":"Sarathy","year":"2023","journal-title":"Expet Opin Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102655_sref20","doi-asserted-by":"crossref","first-page":"20930","DOI":"10.1021\/acs.jmedchem.5c01479","article-title":"Harnessing chimeric degrader technologies for antimicrobial innovation","volume":"68","author":"Poddar","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_sref21","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuaf046","article-title":"PROteolysis TArgeting Chimeras (PROTACs) and beyond: targeted degradation as a new path to fight microbial pathogens","volume":"49","author":"Bazzacco","year":"2025","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.cbpa.2026.102655_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.2c01648","article-title":"Targeted protein degradation induced by HEMTACs based on HSP90","volume":"66","author":"Li","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib23","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1021\/acschembio.4c00422","article-title":"Recruitment to the proteasome is necessary but not sufficient for chemically induced, ubiquitin-independent degradation of native proteins","volume":"19","author":"Balzarini","year":"2024","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib24","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1021\/acs.jmedchem.5c00485","article-title":"ByeTAC: bypassing E-Ligase-Targeting chimeras for direct proteasome degradation","volume":"68","author":"Loy","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chembiol.2024.02.008","article-title":"Selective targeting of Plasmodium falciparum Hsp90 disrupts the 26S proteasome","volume":"31","author":"Mansfield","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.cbpa.2026.102655_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_sref28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.chembiol.2025.02.002","article-title":"VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation","volume":"32","author":"Mangano","year":"2025","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108437","article-title":"Recent advances in PROTAC-based antiviral and antibacterial therapeutics","volume":"160","author":"Zhou","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41589-019-0265-y","article-title":"Structure of McsB, a protein kinase for regulated arginine phosphorylation","volume":"15","author":"Suskiewicz","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib32","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1038\/s41467-024-48506-8","article-title":"Targeted protein degradation in mycobacteria uncovers antibacterial effects and potentiates antibiotic efficacy","volume":"15","author":"Won","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102655_bib33","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41467-020-15516-1","article-title":"Pyrazinamide triggers degradation of its target aspartate decarboxylase","volume":"11","author":"Gopal","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102655_bib34","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1038\/s44319-025-00510-9","article-title":"Targeted protein degradation in Escherichia coli using CLIPPERs","volume":"26","author":"Izert-Nowakowska","year":"2025","journal-title":"EMBO Rep"},{"key":"10.1016\/j.cbpa.2026.102655_sref35","doi-asserted-by":"crossref","first-page":"13149","DOI":"10.1039\/D5CC02015H","article-title":"SsrA-based design of BacPROTACs for \u03b2-lactamase degradation in Gram-negative bacteria","volume":"61","author":"Nie","year":"2025","journal-title":"Chem Commun"},{"key":"10.1016\/j.cbpa.2026.102655_bib36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/ph18060919","article-title":"TrypPROTACs unlocking new therapeutic strategies for Chagas disease","volume":"18","author":"Rodriguez Gini","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cbpa.2026.102655_sref37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41573-024-00933-4","article-title":"Combating antimicrobial resistance in malaria, HIV and tuberculosis","volume":"23","author":"Duffey","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102655_sref38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s44386-025-00006-5","article-title":"Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining","volume":"2","author":"Godinez-Macias","year":"2025","journal-title":"NPJ Drug Discovery"},{"key":"10.1016\/j.cbpa.2026.102655_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpddr.2011.12.001","article-title":"The proteasome of malaria parasites: a multi-stage drug target for chemotherapeutic intervention?","volume":"2","author":"Aminake","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resis"},{"key":"10.1016\/j.cbpa.2026.102655_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092235","article-title":"The ubiquitin proteasome system in genome stability and cancer","volume":"13","author":"Morgan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cbpa.2026.102655_sref41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-05342-0","article-title":"Functional characterisation of components in two Plasmodium falciparum Cullin-RING-Ligase complexes","volume":"15","author":"Marapana","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2026.102655_sref42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.pt.2017.05.009","article-title":"Protein degradation systems as antimalarial therapeutic targets","volume":"33","author":"Ng","year":"2017","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.cbpa.2026.102655_bib43","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102655_bib44","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","article-title":"Development of a GC-376 based peptidomimetic PROTAC as a degrader of 3-Chymotrypsin-like protease of SARS-CoV-2","volume":"15","author":"Grifagni","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.cbpa.2026.102655_bib46","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.3390\/ijms26083903","article-title":"Development of peptidomimetic PROTACs as potential degraders of 3-Chymotrypsin-like protease of SARS-CoV-2","volume":"26","author":"Wei","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cbpa.2026.102655_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116629","article-title":"Development of novel antiviral agents that induce the degradation of the main protease of human-infecting coronaviruses","volume":"275","author":"Cheng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102655_bib48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s43856-025-00863-1","article-title":"Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus","volume":"5","author":"Pan","year":"2025","journal-title":"Commun Med"},{"key":"10.1016\/j.cbpa.2026.102655_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"10.1016\/j.cbpa.2026.102655_bib50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","article-title":"PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication","volume":"31","author":"Emert-Sedlak","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1021\/acschembio.4c00812","article-title":"Workflow for E3 Ligase ligand validation for PROTAC development","volume":"20","author":"Mileti\u0107","year":"2025","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100020","article-title":"Expanding the landscape of E3 ligases for targeted protein degradation","volume":"2","author":"Kramer","year":"2022","journal-title":"Curr Res Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102655_bib53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s44259-024-00023-w","article-title":"Multidrug efflux in Gram-negative bacteria: structural modifications in active compounds leading to efflux pump avoidance","volume":"2","author":"Gurvic","year":"2024","journal-title":"npj Antimicrob Res"},{"key":"10.1016\/j.cbpa.2026.102655_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114502","article-title":"Strategies and progresses for enhancing targeted antibiotic delivery","volume":"189","author":"Nazli","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cbpa.2026.102655_bib55","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1021\/acsinfecdis.5c00047","article-title":"Metabolic activation versus masked prodrugs: bisubstrate mimic inhibitors of CoaBC's PPCS activity in Mycobacterium tuberculosis and Staphylococcus aureus","volume":"11","author":"Kotz\u00e9","year":"2025","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cbpa.2026.102655_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118007","article-title":"Antibiotic conjugates: using molecular Trojan Horses to overcome drug resistance","volume":"186","author":"Li","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cbpa.2026.102655_bib57","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3389\/fimmu.2018.02697","article-title":"Specific MHC-I peptides are induced using PROTACs","volume":"9","author":"Jensen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cbpa.2026.102655_bib58","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.tips.2024.10.006","article-title":"Development of PROTACs using computational approaches","volume":"45","author":"Ge","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cbpa.2026.102655_bib59","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1021\/acs.jcim.3c01878","article-title":"PROTACable Is an Integrative Computational Pipeline of 3-D Modeling and Deep Learning To Automate the De Novo Design of PROTACs","volume":"64","author":"Mslati","year":"2024","journal-title":"J Chem Inf Model"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:28:56Z","timestamp":1776158936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593126000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":59,"alternative-id":["S1367593126000049"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102655","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted protein degradation as a novel therapeutic strategy against infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102655"}}